The antifibrotic drug halofuginone inhibits proliferation and collagen production by human leiomyoma and myometrial smooth muscle cells
about
Proceedings from the Third National Institutes of Health International Congress on Advances in Uterine Leiomyoma Research: comprehensive review, conference summary and future recommendationsTransforming growth factor β signaling in uterine development and functionProceedings from theNational Institute of Child Health and Human Development conference on the Uterine Fibroid Research Update Workshop.Racial and ethnic differences in the pathogenesis and clinical manifestations of uterine leiomyoma.Increased serum oxidative stress markers in women with uterine leiomyomaValidation of the aging hen (Gallus gallus domesticus) as an animal model for uterine leiomyomasHalofuginone inhibits phosphorylation of SMAD-2 reducing angiogenesis and leukemia burden in an acute promyelocytic leukemia mouse model.Role of microRNA-21 and programmed cell death 4 in the pathogenesis of human uterine leiomyomas.Estrogen Regulates MAPK-Related Genes through Genomic and Nongenomic Interactions between IGF-I Receptor Tyrosine Kinase and Estrogen Receptor-Alpha Signaling Pathways in Human Uterine Leiomyoma Cells.Treatment for Uterine Fibroids: Searching for Effective Drug Therapies.Expression profiling of nuclear receptors identifies key roles of NR4A subfamily in uterine fibroids.Halofuginone suppresses growth of human uterine leiomyoma cells in a mouse xenograft modelHalofuginone - the multifaceted molecule.Profibrotic interleukin-33 is correlated with uterine leiomyoma tumour burden.Pharmacological therapeutics targeting the secondary defects and downstream pathology of Duchenne muscular dystrophyTranilast Inhibits Genes Functionally Involved in Cell Proliferation, Fibrosis, and Epigenetic Regulation and Epigenetically Induces miR-29c Expression in Leiomyoma Cells.
P2860
Q24567733-1F77C605-B4E9-43B5-AC74-ACFD3047020BQ26824939-1A6D5790-EFE3-4BC6-A5FC-3E0C5E128BCFQ34124951-8CB2C2EB-448E-49E7-B6F5-C28684C0581DQ34223004-119E59A4-F4F5-4FEE-937A-2DC3D81DEDA9Q34951145-3B7DC9A9-BF93-46C0-97A5-5C00CDF9626AQ35617355-F66D498A-90B6-421B-99C7-770206EE404EQ35800540-06607F4B-EEE4-4951-BC9E-83B6FD576C24Q36205226-5BD00306-AF91-49F3-9CB0-CEF78FD2BC86Q36326856-8E3FB99F-5D07-48C8-A081-735DBE75EA89Q36476226-5DCB743C-CE6D-451D-9720-CA2C2E52E504Q36789291-CA2D382E-F045-4800-B60C-5B07C0322172Q36991838-B44CDBC3-DF4B-4E0A-B363-0BAD22FE52C5Q38311322-F4DD219E-4D46-4FA8-8A94-89804F76727FQ39406925-D412BFA7-6F79-4F02-B15C-D6D9A2B6255FQ39410461-8A8E7F22-C37D-4C28-9EB0-8798A6E6E8F3Q51173383-8C8C3073-4924-4CE8-BCDC-91D4A16DB1F7
P2860
The antifibrotic drug halofuginone inhibits proliferation and collagen production by human leiomyoma and myometrial smooth muscle cells
description
2009 nî lūn-bûn
@nan
2009 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
The antifibrotic drug halofugi ...... myometrial smooth muscle cells
@ast
The antifibrotic drug halofugi ...... myometrial smooth muscle cells
@en
type
label
The antifibrotic drug halofugi ...... myometrial smooth muscle cells
@ast
The antifibrotic drug halofugi ...... myometrial smooth muscle cells
@en
prefLabel
The antifibrotic drug halofugi ...... myometrial smooth muscle cells
@ast
The antifibrotic drug halofugi ...... myometrial smooth muscle cells
@en
P2093
P2860
P1476
The antifibrotic drug halofugi ...... myometrial smooth muscle cells
@en
P2093
Meagan M Grudzien
Melissa Arredondo
Peter C Manning
Philip Steven Low
Robert J Belton
Romana A Nowak
P2860
P304
P356
10.1016/J.FERTNSTERT.2008.11.018
P407
P577
2009-01-09T00:00:00Z